Ser1916
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser1916  -  MYH9 (human)

Site Information
AMNREVssLkNkLRr   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 451181

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 19 ) , immunoassay ( 5 ) , immunoprecipitation ( 17 ) , mass spectrometry ( 6 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 ) , mutation of modification site ( 1 , 4 , 5 ) , peptide sequencing ( 19 ) , phospho-antibody ( 1 , 3 , 4 , 5 ) , phosphoamino acid analysis ( 17 ) , phosphopeptide mapping ( 19 ) , western blotting ( 1 , 3 , 4 , 5 , 17 )
Disease tissue studied:
bone cancer ( 5 ) , breast cancer ( 1 , 4 , 6 , 8 , 17 ) , breast ductal carcinoma ( 6 ) , breast cancer, triple negative ( 6 ) , ovarian cancer ( 6 )
Relevant cell line - cell type - tissue:
breast ( 6 ) , COS7 (fibroblast) ( 4 ) , HEK293T (epithelial) ( 1 ) , HUVEC (endothelial) ( 3 ) , Jurkat (T lymphocyte) ( 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 ) , MCF-7 (breast cell) ( 1 ) , MDA-MB-231 (breast cell) ( 4 , 8 , 17 ) , ovary ( 6 ) , platelet-blood ( 19 ) , U2OS (bone cell) ( 5 )

Upstream Regulation
Regulatory protein:
HBXIP (human) ( 1 ) , RAC1 (human) ( 5 )
Putative in vivo kinases:
CK2A1 (human) ( 3 ) , CK2B (human) ( 3 ) , PKCB (human) ( 1 ) , PKCB iso2 (human) ( 5 )
Kinases, in vitro:
PKCA (human) ( 17 , 18 , 19 )
Treatments:
cell spreading ( 5 , 8 ) , CGP53353 ( 5 ) , collagen ( 5 ) , EGF ( 17 ) , fibronectin ( 5 ) , Go_6976 ( 5 ) , LY333531 ( 1 ) , NKH_477 ( 3 ) , phorbol_ester ( 5 ) , siRNA ( 1 )

Downstream Regulation
Effects of modification on MYH9:
intracellular localization ( 4 , 5 ) , molecular association, regulation ( 1 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 ) , cell adhesion, altered ( 5 ) , cell adhesion, induced ( 4 ) , cell motility, induced ( 1 , 5 ) , cytoskeletal reorganization ( 1 , 4 , 5 ) , exocytosis, induced ( 3 )
Induce interaction with:
HBXIP (human) ( 1 )

References 

1

Zhang L, et al. (2023) HBXIP blocks myosin-IIA assembly by phosphorylating and interacting with NMHC-IIA in breast cancer metastasis. Acta Pharm Sin B 13, 1053-1070
36970214   Curated Info

2

Ye G, et al. (2020) Nuclear MYH9-induced CTNNB1 transcription, targeted by staurosporin, promotes gastric cancer cell anoikis resistance and metastasis. Theranostics
32685004   Curated Info

3

Li P, et al. (2017) Myosin IIa is critical for cAMP-mediated endothelial secretion of von Willebrand factor. Blood
29208598   Curated Info

4

Rai V, Thomas DG, Beach JR, Egelhoff TT (2017) Myosin IIA Heavy Chain Phosphorylation Mediates Adhesion Maturation and Protrusion in Three Dimensions. J Biol Chem 292, 3099-3111
28053086   Curated Info

5

Pasapera AM, et al. (2015) Rac1-Dependent Phosphorylation and Focal Adhesion Recruitment of Myosin IIA Regulates Migration and Mechanosensing. Curr Biol 25, 175-86
25544611   Curated Info

6

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

7

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

8

Betapudi V, Gokulrangan G, Chance MR, Egelhoff TT (2011) A Proteomic Study of Myosin II Motor Proteins during Tumor Cell Migration. J Mol Biol 407, 673-86
21316371   Curated Info

9

Possemato A (2010) CST Curation Set: 9613; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

10

Zhou J (2009) CST Curation Set: 5904; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

11

Zhou J (2009) CST Curation Set: 5905; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

12

Zhou J (2008) CST Curation Set: 5472; Year: 2008; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

13

Zhou J (2008) CST Curation Set: 5473; Year: 2008; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

14

Zhou J (2008) CST Curation Set: 5474; Year: 2008; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

15

Zhou J (2008) CST Curation Set: 5475; Year: 2008; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

16

Possemato A (2008) CST Curation Set: 3962; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

17

Dulyaninova NG, House RP, Betapudi V, Bresnick AR (2007) Myosin-IIA heavy-chain phosphorylation regulates the motility of MDA-MB-231 carcinoma cells. Mol Biol Cell 18, 3144-55
17567956   Curated Info

18

Kriajevska M, et al. (1998) Metastasis-associated Mts1 (S100A4) protein modulates protein kinase C phosphorylation of the heavy chain of nonmuscle myosin. J Biol Chem 273, 9852-6
9545325   Curated Info

19

Conti MA, Sellers JR, Adelstein RS, Elzinga M (1991) Identification of the serine residue phosphorylated by protein kinase C in vertebrate nonmuscle myosin heavy chains. Biochemistry 30, 966-70
1899200   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.